

Supplementary Table 2. Prescription status of quadruple combination of OHAs in study population at baseline

Quadruple combinations (<i>n</i> = 357)				No. (%)
Metformin	Sulfonylurea or glinide	DPP4 inhibitor	Thiazolidinedione	226 (63.3)
			SGLT2 inhibitor	67 (18.8)
			α-Glucosidase inhibitor	15 (4.2)
	DPP4 inhibitor	Thiazolidinedione	SGLT2 inhibitor	12 (3.4)
			α-Glucosidase inhibitor	7 (2.0)
			SGLT2 inhibitor	6 (1.7)
			SGLT2 inhibitor	20 (5.6)
Sulfonylurea or glinide	Thiazolidinedione	DPP4 inhibitor	2 (0.5)	
		α-Glucosidase inhibitor	2 (0.5)	

OHA, oral hypoglycemic agent; DPP4, dipeptidyl peptidase 4; SGLT2, sodium-glucose cotransporter 2.